Small Cap
April 29, 2026
Benjamin Graham's 1949 Mr. Market parable is the operating system for ignoring daily price quotes. Titan Biotech FY25's audited quiet — ₹3 cr borrowings, 103% CFO/PAT, 36.4% ROCE — illustrates the underlying factory that survives every tick.
April 8, 2026
When investors evaluate a company, they zoom straight to revenue and profit. But the Other Income line reveals the true quality of earnings. We analyse 12 years of Titan Biotech's Other Income data to prove its profits are genuinely driven by core operations — not one-time windfalls.
April 8, 2026
In the world of fundamental analysis, most investors obsess over revenue growth, profit margins, and return ratios. These are important metrics, no doubt. But there is […]
